Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Multiple Myeloma Clinical Trial

Official title:

Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04405167
• Other study ID #: 842603, UPCC 45419
• Secondary ID: UPCC 45419
• Status: Recruiting
• Phase: Phase 1
• Start date: July 10, 2020
• Est. completion date: July 2025

Study information

• Verified date: November 2023
• Source: University of Pennsylvania
• Contact: Dan Vogl, MD
• Phone: 215-662-7140
• Email: dan.vogl[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Description:

Tasquinimod has previously been studied as an anti-cancer agent in patients with other cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer that showed an improvement in radiographic progression-free survival. The side effect profile of tasquinimod is well-characterized based on this previous experience. This trial will establish a maximum tolerated dose and optimal schedule for administration of tasquinimod in patients with multiple myeloma and then investigate the maximum tolerated dose of tasquinimod in combination with a standard myeloma regimen of ixazomib, lenalidomide, and dexamethasone (IRd). For both single agent tasquinimod and the combination of tasquinimod with IRd, exploratory expansion cohorts will be enrolled to preliminarily characterize the antimyeloma activity of each regimen.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: July 2025
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent

2. 18 years of age or older

3. Multiple myeloma (MM) diagnosed according to IMWG criteria

4. Measurable disease (this is defined differently in different arms)

5. Multiple myeloma relapsed or refractory to treatment (this is defined differently in different arms)

6. Meet certain clinical laboratory criteria

7. ECOG performance status =2

8. Life expectancy of at least 3 months

9. For women of childbearing potential, a negative serum or urine pregnancy test prior to study treatment.

10. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two methods of contraception one of which must be highly effective

11. For men: agreement to use a barrier method of contraception for 1 month before start of study treatment, during the treatment period and for 6 months after the last dose of study treatment.

Exclusion Criteria:

1. Failure to have fully recovered (i.e. = Grade 1 toxicity) from the effects of prior chemotherapy (except for alopecia)

2. Active graft versus host disease

3. Treatment with any of the following:

1. Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment

2. Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to the initiation of study treatment

3. Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter

4. Systemic corticosteroids >=10 mg prednisone or equivalent within 7 days prior to the initiation of study treatment

5. Radiotherapy within 7 days prior to initiating study treatment

6. Plasmapheresis within 4 weeks prior to the initiation of study treatment

7. Tasquinimod at any time

4. Known central nervous system involvement by myeloma

5. Diagnosis of smoldering multiple myeloma

6. Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

7. Active plasma cell leukemia

8. Symptomatic primary (AL) amyloidosis

9. Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome

10. Active other malignancy

11. Major surgery within 4 weeks prior to initiating study treatment

12. Evidence of severe or currently uncontrolled cardiovascular condition

13. Ongoing or active systemic infection that requires systemic antibiotic or parenteral anti-infective therapy

14. Active tuberculosis, active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive

15. History of pancreatitis

16. History of malabsorption or other condition that would interfere with absorption of study drugs

17. Systemic treatment within 14 days prior to the initiation of study treatment with moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4 (CYP3A4)

18. Need for ongoing therapy drug substances of narrow therapeutic range that are metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole, terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine)

19. Need for ongoing therapy with drug substances of narrow therapeutic range metabolized mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron)

20. Ongoing treatment with warfarin, unless the INR is <=3.0.

21. For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis prophylaxis

22. Peripheral neuropathy grade =2 (NCI-CTCAE)

23. Known hypersensitivity to tasquinimod or any excipients in the study treatments

24. Pregnant or nursing (lactating) women

25. Any other condition that would, in the Investigator's judgment, contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures

26. Prior inclusion in this study

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Tasquinimod
Tasquinimod will be supplied as oral capsules.
• IRd chemotherapy
IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
University of Pennsylvania	Active Biotech AB

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimal Dose	Maximum tolerated dose of single agent tasquinimod (mg).	approximately 3 years
Secondary	Preliminary Single-Agent Toxicity Profile	Percentage of subjects experiencing treatment-emergent grade 3/4 adverse events during therapy with single-agent tasquinimod (using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 5)	approximately 3 years
Secondary	Preliminary Combination Therapy Toxicity Profile	Percentage of subjects experiencing treatment-emergent grade 3/4 adverse events during therapy with tasquinimod, ixazomib, lenalidomide, and dexamethasone (using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 5)	approximately 3 years
Secondary	Preliminary Single-Agent Response	Percentage of subjects achieving a partial response or better with single-agent tasquinimod (using the response criteria of the International Myeloma Working Group)	approximately 3 years
Secondary	Preliminary Assessment of Clinical Response Combination Therapy	Percentage of subjects achieving a partial response or better with tasquinimod, ixazomib, lenalidomide, and dexamethasone (using the response criteria of the International Myeloma Working Group)	approximately 3 years